Analysis of the Anticancer Drug List between the National Essential Medicines List (2018) and the WHO Model List of Essential Medicines (2017)
YAN Jia-qing1, LIU Min1, ZHANG Yuan1, MA Ying-lin1, LE Kai-di1, SHEN Xin1, CAO Xiu-ping2, LI Guo-hui1*
1. Department of Pharmacy, National Cancer Center, National Clinical Research Center for Cancer, Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100021, China; 2. Chinese Pharmaceutical Association, Beijing 100050,China
Abstract：OBJECTIVE To analyze the variation of the anticancer drug list in the National Essential Medicines List (NEML-2018) and compare with the WHO Essential Model List (WHO-EML-2017) considering the epidemic characteristics and current national conditions, in order to provide the reference and advice for the revision of NEML in the future.METHODS The category, content, formulation, dosage forms, medicines for children and indication for use of anticancer drug list between the NEML-2018 and WHO-EML-2017 were compared, and the deficiency existing in the NEML-2018 was analyzed.RESULTS Compared with the NEML-2012, the category and content of the anticancer drug list have been improved in the 2018th edition, which is more reasonable for clinical request. However, disadvantages still exist in the aspect of the content, formulation, dosage forms, medicines for children and indication for use compared with the WHO-EML-2017.CONCLUSION Although the rationality of the category and content has been improved in the NEML-2018, it still needs to be further improved compared with the WHO-EML-2017, which provides guidance and indication for the revision of anticancer drug list of the NEML in the future.
闫加庆, 刘敏, 张元, 马颖林, 乐凯迪, 沈鑫, 曹秀萍, 李国辉. 《国家基本药物目录》(2018)与WHO《基本药物示范目录》(2017)中抗肿瘤药物的比较和分析[J]. 中国药学杂志, 2019, 54(22): 1901-1906.
YAN Jia-qing, LIU Min, ZHANG Yuan, MA Ying-lin, LE Kai-di, SHEN Xin, CAO Xiu-ping, LI Guo-hui. Analysis of the Anticancer Drug List between the National Essential Medicines List (2018) and the WHO Model List of Essential Medicines (2017). Chinese Pharmaceutical Journal, 2019, 54(22): 1901-1906.
XUE Y H, LI J. Decipherment and consideration of national essential medicines list (2018 edition) [J]. Herald Med(医药导报),2019, 38(1):1-8.
[2]
WHO. WHO Model Lists of Essential Medicines 20th edition [EB/OL] (2017-03-12) [2019-06-06]. https://www.who.int/medicines/publications/essentialmedicines/en/.
[3]
ZUO W, SUN W J, TANG X W, et al. Analysis of the antibacterial list between the National Essential Medicines List and the WHO Model List of Essential Medicines (2017) [J]. Clin Med J(临床药物治疗杂志),2018, 16(10):26-31.
[4]
NATIONAL HEALTH COMMISSION OF THE PEOPLE′S REPUBLIC OF CHINA. National Essential Medicines List (2018 Edition) [EB/OL]. (2018-10-25) [2019-06-06]. http://www.nhc.gov.cn/yaozs/s7656/201810/c18533e22a3940d08d996b588d941631.shtml.
[5]
NATIONAL HEALTH COMMISSION OF THE PEOPLE′S REPUBLIC OF CHINA. Decipherment and Consideration of National Essential Medicines List(2018 Edition) [EB/OL]. (2018-10-25) [2018-10-25]. http://www.nhc.gov.cn/yaozs/s7656/201810/c18533e22a3940d08d996b588d941631.shtml.
[6]
ZHANG S S, WU T, ZHANG R, et al. Interpretation of the 2018 Edition of the National Essential Drugs List [J]. Health Econom Res (卫生经济研究),2019, 36(6):47-50.
[7]
ZHOU R R, XIE X H, CHEN Z, et al. Comparative analysis of WHO Model List of Essential Medicines for Children (the 5th and 6th editions) and Chinese National Essential Medicine List (2012 edition) and its implication for China [J]. Chin J New Drugs (中国新药杂志), 2018, 27(19):2221-2226.
[8]
CHEN Y F, BIAN Y Y. Comparisons of the 2015 edition of WHO model list of essential medicines for children and the 2012 edition of list of national essential medicines for children [J]. J Int Pharm Res (国际药学研究杂志), 2016, 43(4):602-607.
[9]
CHEN Z, XIE X H, WANG X L, et al. Comparative analysis of each edition of WHO Model List of Essential Medicines for Children and Chinese National Essential Medicine List (2012 edition) [J]. Chin J New Drugs (中国新药杂志), 2016, 25(13):1451-1455.
[10]
BRAY F, FERLAY J, SOERJOMATARAM I, et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries [J]. CA Cancer J Clin, 2018, 68(6):394-424.
[11]
CHEN W Q, ZHENG R S, BAADE P D, et al. Cancer statistics in China, 2015 [J]. CA Cancer J Clin, 2016, 66(2):115-132.
[12]
WANG L J, XU W J, CHEN W, et al. Comparative analysis between the National Essential Medicines List and the WHO 2011 Model List [J]. Chin J Health Policy(中国卫生政策研究), 2012, 5(7):21-25.
[13]
CHEN J, NIE Q, LIU Y. Comparison and reference of the dynamic adjustment procedure for WHO Essential Medicine Demonstration List and National Essential Medicine List in China [J]. J China Pharm (中国药房), 2015, 26(3):289-293.
2019, Vol. 54 
